Patent
The present disclosure provides a Paenibacillus strain, and a hemostatic polysaccharide produced by same and use thereof. In the present disclosure, a Paenibacillus sp. 1229 has a deposit number of CCTCC NO: M 2022553. A produced exopolysaccharide (EPS) Hemoadhican has a hemostatic function, and can be prepared as a hemostatic material in different dosage forms for different types of hemostasis. The hemostatic material has a high hemostatic speed, no need for applying pressures to the wound for a long time, safety and non-toxicity, desirable biocompatibility, and no requirement of removal after use. The material is suitable for the application of hemostasis in irregular bleeding such as solid organs in vitro or in vivo and diffuse bleeding.
1 . A hemostatic material, comprising an exopolysaccharide (EPS) Hemoadhican produced by a Paenibacillus sp. 1229 with a deposit number of CCTCC NO: M 2022553, the EPS Hemoadhican has a structural formula as follows:
wherein n is 100 to 100,000; the EPS Hemoadhican comprises glucose, mannose, galactose, and rhamnose in a molar ratio of 2:1:1:1, and has a glycosidic bond linkage as follows:→)-α-L-Rhap-(1→3)-β-D-Glcp-(1→4) [4,6-ethylene-α-D-Galp-(1→4)-α-D-Glc-( 1 →3)]-α-D-Manp-(1→.
2 . The hemostatic material according to claim 1 , wherein the hemostatic material comprises the EPS Hemoadhican alone, or comprises the EPS Hemoadhican and a medically acceptable auxiliary material, or comprises the EPS Hemoadhican and other drugs, or comprises the EPS Hemoadhican, the medically acceptable auxiliary material, and the other drugs.
3 . The hemostatic material according to claim 1 , wherein the hemostatic material has a dosage form selected from the group consisting of a powder, a sponge, and a gel.
4 . The hemostatic material according to claim 1 , wherein the hemostatic material is used for treating visceral hemorrhage, arterial hemorrhage, or coagulopathy hemorrhage.